

**JAZZ PHARMACEUTICALS PLC**  
**RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION - 2020 BY QUARTER**

To supplement Jazz Pharmaceuticals plc's financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures. The tables that follow present certain financial information on a GAAP reported and non-GAAP adjusted basis for Jazz Pharmaceuticals plc and its consolidated subsidiaries for the periods specified, along with reconciliations of the non-GAAP financial measures presented to the most directly comparable GAAP reported measures. The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions.

The non-GAAP financial measures included in the accompanying tables are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. For example, commencing in 2020, the company no longer excludes upfront and milestone payments from the company's non-GAAP adjusted net income, its line item components and non-GAAP adjusted EPS. Accordingly, such payments are not excluded from its non-GAAP financial measures for the three and six months ended June 30, 2020 as detailed in the reconciliation tables that follow. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by the company in the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

**JAZZ PHARMACEUTICALS PLC**  
**RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION - 2020 BY QUARTER**

In thousands, except per share amounts (Unaudited)	1Q20	2Q20	1H20
<b>GAAP reported net income (loss)</b>	<b>\$ (157,833)</b>	<b>\$ 114,801</b>	<b>\$ (43,032)</b>
Intangible asset amortization	62,847	62,974	125,821
Share-based compensation expense	28,654	30,604	59,258
Impairment charge <sup>(a)</sup>	136,139	-	136,139
Non-cash interest expense <sup>(b)</sup>	12,000	12,793	24,793
Loss on extinguishment of debt	-	4,475	4,475
Income tax effect of above adjustments	(55,974)	(18,331)	(74,305)
Non-GAAP adjusted net income	<u>\$ 25,833</u>	<u>\$ 207,316</u>	<u>\$ 233,149</u>
<b>GAAP reported net income (loss) per diluted share</b>	<b>(2.82)</b>	<b>2.06</b>	<b>(0.77)</b>
Non-GAAP adjusted net income per diluted share	0.45	3.71	4.14
Weighted-average ordinary shares used in diluted per share calculation - GAAP	55,956	55,864	55,684
Weighted-average ordinary shares used in diluted per share calculation - non-GAAP	<u>56,792</u>	<u>55,864</u>	<u>56,328</u>

Explanation of Adjustments and Certain Line Items (in thousands):

(a) Impairment charge related to the company's decision to stop enrollment in its Phase 3 clinical study of defibrotide for the prevention of veno-occlusive disease (VOD) due to a determination by an Independent Data Monitoring Committee that it is highly unlikely that the study will reach its primary endpoint.

(b) Non-cash interest expense associated with debt discount and debt issuance costs.

**JAZZ PHARMACEUTICALS PLC**  
**RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION**  
**CERTAIN LINE ITEMS - 2020 BY QUARTER**

Period	In thousands (Unaudited)	Cost of product sales	Gross margin	Selling, general and administrative	Research and development	Intangible asset amortization	Impairment charge	Interest expense, net	Income tax provision (benefit)	Effective tax rate
<b>1H20</b>	<b>GAAP Reported</b>	<b>\$ 56,665</b>	<b>94.8%</b>	<b>\$ 399,806</b>	<b>\$ 165,029</b>	<b>\$ 125,821</b>	<b>\$ 136,139</b>	<b>\$ 44,706</b>	<b>\$ 3,467</b>	<b>(9.2%)</b>
	Non-GAAP Adjustments									
	Intangible asset amortization	-	-	-	-	(125,821)	-	-	-	-
	Share-based compensation expense	(3,594)	0.3	(41,616)	(14,048)	-	-	-	-	-
	Impairment charge	-	-	-	-	-	(136,139)	-	-	-
	Non-cash interest expense	-	-	-	-	-	-	(24,793)	-	-
	Loss on extinguishment of debt	-	-	-	-	-	-	(4,475)	-	-
	Income tax effect of above adjustments	-	-	-	-	-	-	-	74,305	34.1
	Total of Non-GAAP adjustments	(3,594)	0.3	(41,616)	(14,048)	(125,821)	(136,139)	(29,268)	74,305	34.1
	Non-GAAP Adjusted	<b>\$ 53,071</b>	<b>95.1%</b>	<b>\$ 358,190</b>	<b>\$ 150,981</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 15,438</b>	<b>\$ 77,772</b>	<b>24.9%</b>
<b>2Q20</b>	<b>GAAP Reported</b>	<b>\$ 28,008</b>	<b>95.0%</b>	<b>\$ 191,406</b>	<b>\$ 78,922</b>	<b>\$ 62,974</b>	<b>\$ -</b>	<b>\$ 26,210</b>	<b>\$ 54,754</b>	<b>31.9%</b>
	Non-GAAP Adjustments									
	Intangible asset amortization	-	-	-	-	(62,974)	-	-	-	-
	Share-based compensation expense	(1,921)	0.3	(21,020)	(7,663)	-	-	-	-	-
	Non-cash interest expense	-	-	-	-	-	-	(12,793)	-	-
	Loss on extinguishment of debt	-	-	-	-	-	-	(4,475)	-	-
	Income tax effect of above adjustments	-	-	-	-	-	-	-	18,331	(6.0)
	Total of Non-GAAP adjustments	(1,921)	0.3%	(21,020)	(7,663)	(62,974)	-	(17,268)	18,331	(6.0)
	Non-GAAP Adjusted	<b>\$ 26,087</b>	<b>95.3%</b>	<b>\$ 170,386</b>	<b>\$ 71,259</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 8,942</b>	<b>\$ 73,085</b>	<b>25.9%</b>
<b>1Q20</b>	<b>GAAP Reported</b>	<b>\$ 28,657</b>	<b>94.6%</b>	<b>\$ 208,400</b>	<b>\$ 86,107</b>	<b>\$ 62,847</b>	<b>\$ 136,139</b>	<b>\$ 18,496</b>	<b>\$ (51,287)</b>	<b>24.5%</b>
	Non-GAAP Adjustments									
	Intangible asset amortization	-	-	-	-	(62,847)	-	-	-	-
	Share-based compensation expense	(1,673)	0.3	(20,596)	(6,385)	-	-	-	-	-
	Impairment charge	-	-	-	-	-	(136,139)	-	-	-
	Non-cash interest expense	-	-	-	-	-	-	(12,000)	-	-
	Income tax effect of above adjustments	-	-	-	-	-	-	-	55,974	(9.1)
	Total of Non-GAAP adjustments	(1,673)	0.3	(20,596)	(6,385)	(62,847)	(136,139)	(12,000)	55,974	(9.1)
	Non-GAAP Adjusted	<b>\$ 26,984</b>	<b>94.9%</b>	<b>\$ 187,804</b>	<b>\$ 79,722</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 6,496</b>	<b>\$ 4,687</b>	<b>15.4%</b>